Cargando…
Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis: Real-world Evidence From the GENERATE Registry
BACKGROUND AND OBJECTIVES: To determine the real-world use of rituximab in autoimmune encephalitis (AE) and to correlate rituximab treatment with the long-term outcome. METHODS: Patients with NMDA receptor (NMDAR)-AE, leucine-rich glioma-inactivated-1 (LGI1)- AE, contactin-associated protein-like-2...
Autores principales: | Thaler, Franziska S., Zimmermann, Luise, Kammermeier, Stefan, Strippel, Christine, Ringelstein, Marius, Kraft, Andrea, Sühs, Kurt-Wolfram, Wickel, Jonathan, Geis, Christian, Markewitz, Robert, Urbanek, Christian, Sommer, Claudia, Doppler, Kathrin, Penner, Loana, Lewerenz, Jan, Rößling, Rosa, Finke, Carsten, Prüss, Harald, Melzer, Nico, Wandinger, Klaus-Peter, Leypoldt, Frank, Kümpfel, Tania |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488759/ https://www.ncbi.nlm.nih.gov/pubmed/34599001 http://dx.doi.org/10.1212/NXI.0000000000001088 |
Ejemplares similares
-
Management and prognostic markers in patients with autoimmune encephalitis requiring ICU treatment
por: Schubert, Julia, et al.
Publicado: (2018) -
Seizure Semiology in Antibody-Associated Autoimmune Encephalitis
por: Kaaden, Tillman, et al.
Publicado: (2022) -
CSF Findings in Acute NMDAR and LGI1 Antibody–Associated Autoimmune Encephalitis
por: Dürr, Marc, et al.
Publicado: (2021) -
Generate-Boost: study protocol for a prospective, multicenter, randomized controlled, double-blinded phase II trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitis
por: Wickel, Jonathan, et al.
Publicado: (2020) -
Genome-wide Association Study Identifies 2 New Loci Associated With Anti-NMDAR Encephalitis
por: Tietz, Anja K., et al.
Publicado: (2021)